

Supplementary material

Cylke-Falkowska K, Czajka-Oraniec I, Stelmachowska-Banaś M, Zgliczyński W. Immune checkpoint inhibitor–induced central diabetes insipidus in the course of panhypophysitis. Pol Arch Intern Med. 2024; 134: 16672. doi:10.20452/pamw.16672

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1

| Hormonal test | Baseline results | Follow-up (4months) | Follow-up (15 months) | Normal range |
|------------------|------------------|---------------------|-----------------------|--------------|
| Cortisol [ug/dl] | 1.0 | 2.0 | <0.5 | 6-18.4 |
| ACTH [pg/ml] | 3.1 | 1.6 | 2.3 | 6-46 |
| DHEA-S [ug/dl] | 7 | 6 | 5 | 97-392 |
| TSH [mIU/l] | 0.004 | 0.005 | 0.564 | 0.35-4 |
| fT4 [pmol/l] | 8.96 | 15.15 | 10.62* | 10.29-22.7 |
| GH [ug/l] | <0.05 | <0.05 | <0.05 | 4.04-15.2 |
| LH [mIU/ml] | 0.3 | 0.4 | <0.2 | 2.15-2.6 |
| FSH [IU/l] | 1.5 | 0.9 | 0.4 | 1.3-11.8 |
| PRL [ng/ml] | <0.5 | 2.0 | <0.5 | 4.04-15.2 |
| TEST [ng/ml] | <0.07 | 0.07 | 5.48** | 1.75-7.81 |
| IGF-1 [ng/ml] | 167 | 91.1 | 72 | 72-225 |

*- during L-thyroxin replacement therapy

** - during testosterone replacement therapy